Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patietnts With Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer Clinical Trial

Official title:

An Open-label, Dose-finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00094835
• Other study ID #: 20040153
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 27, 2004
• Last updated: May 30, 2014
• Start date: January 2005
• Est. completion date: March 2007

Study information

• Verified date: May 2014
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung cancer (NSCLC). - To establish the pharmacokinetic (PK) profile of motesanib when it is used in combination with CP, with panitumumab, or with CP and panitumumab. - To compare the paclitaxel and motesanib PK profiles when the medications are administered 30 minutes (min) or approximately 48 hours (hrs) apart. - To characterize the panitumumab and paclitaxel exposure in the combination regimens of motesanib with CP, motesanib with panitumumab, or motesanib with CP and panitumumab. - To describe the objective response rate (ORR) in each dose cohort. - To measure the immunogenicity of panitumumab in patients administered motesanib with panitumumab and motesanib with CP and panitumumab.

Description:

This was a multicenter, open-label, dose-finding clinical trial examining the safety and PK of once or twice daily motesanib administered with CP or with CP and panitumumab in chemotherapy naïve patients, and with panitumumab in patients with no more than one prior chemotherapy regimen for NSCLC.

Participants were enrolled into the Panitumumab + Paclitaxel + Carboplatin + Motesanib once a safe and tolerable dose of AMG 706 was established in the other treatment arms.

Other known NCT identifiers

• NCT00107224

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: March 2007
• Est. primary completion date: March 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of unresectable stage IIIB or IV non-small cell lung cancer (NSCLC)

• No more than one prior chemotherapy

• Adequate hematologic, renal and hepatic function

• Measurable disease or evaluable disease on CAT scan or MRI

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Able to fast for 10 hrs twice during the study - Able to tolerate oral medications

• Life expectancy of at least 3 months

Exclusion Criteria:

• Symptomatic or untreated central nervous system metastases requiring current treatment

• History of arterial thrombosis within 1 year prior to enrollment

• Anticoagulant therapy, except for warfarin of less than 2mg per day

• Symptomatic peripheral neuropathy

• History of pulmonary hemorrhage or hemoptysis

• Myocardial infarction within 1 year before enrollment

• Uncontrolled hypertension [diastolic greater than 85 mmHg; systolic greater than 145 mmHg]

• History of other cancer, unless treated with no known active disease for longer than 3 years

• Previous treatment with AMG 706 or panitumumab, previous treatment with inhibitors of VEGF or EGF

• No antibody treatment for 6 weeks prior to enrollment

• Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Biological:
• Panitumumab
9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.

Drug:
• Motesanib diphosphate
Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
• Paclitaxel
Paclitaxel 200 mg/m^2 administered by IV infusion over 3 hours.
• Carboplatin
Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

References & Publications (1)

Blumenschein GR Jr, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 1;16(1):279-90. doi: 10.1158/1078-0432.CCR-09-1675. Epub 2009 Dec 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1	The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 1. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.	Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1	The maximal observed plasma concentration of motesanib after a single dose dose in Cycle 1. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.	Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1	The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/?z. The terminal elimination rate constant (?z) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.	Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours postdose.	No
Primary	Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1	Area under the plasma concentration-time curve for motesanib in Cycle 1 calculated using the using the linear/log trapezoidal method. AUC from time zero to infinity (AUC0-inf) is reported for the 50 and 125 mg QD cohorts and AUC from time 0 to 24 hours post-dose (AUC0-24) is reported for the 75 mg BID cohort, where AUC0-24 is the sum of AUC0-12 for the first and second daily dose.	Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1	The trough plasma concentration for motesanib at 24 hours postdose in Cycle 1. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).	Cycle 1, Day 3, 24 hours post-dose	No
Primary	Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2	The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 2. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.	Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2	The maximal observed plasma concentration of motesanib in Cycle 2, after multiple doses. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.	Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2	The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/?z. The terminal elimination rate constant (?z) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.	Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2	Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) for motesanib in Cycle 2 calculated using the using the linear/log trapezoidal method. For the 75 mg BID cohort AUC0-24 is the sum of AUC0-12 for the first and second daily dose.	Cycle 2, Day 1 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.	No
Primary	Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2	The trough plasma concentration for motesanib at 24 hours postdose in Cycle 2. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).	Cycle 2, Day 1, 24 hours post-dose	No
Secondary	Percentage of Participants With an Overall Objective Response	Confirmed objective tumor response defined as a complete response (CR) or partial response (PR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Tumor response was evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI). Responding disease (CR or PR) was confirmed no less than 4 weeks after the criteria for response were first met. A complete response defined as the disappearance of all target lesions and all non-target lesions, no new lesions and normalization of tumor marker level. Partial response defined as either the disappearance of all target lesions and the persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diamer (LD) of target lesions, taking as reference the baseline sum LD and no new lesions and/or unequivocal progression of existing non-target lesions.	After 9 weeks of treatment (at the end of Cycle 3)	No

External Links

•   AmgenTrials clinical trials website